Lercanidipine Viatris (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels on arterial smooth‑muscle cells, preventing calcium entry. This relaxation of vascular smooth muscle leads to vasodilation, decreased peripheral resistance, and a subsequent reduction in systemic blood pressure.

The appropriate dose of lercanidipine is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may be associated with a lower incidence of peripheral edema, but individual response varies and the choice depends on clinical judgment.

Lercanidipine tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Lercanidipine is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, include angioedema, severe hypotension, myocardial infarction, and significant hepatic dysfunction. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, chest pain, or signs of liver injury.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors.